Abstract
Evidence from experimental and genetic studies suggest the existence of a potential link between the leukotrienes (LT) signalling cascade, and the pathogenesis/progression of atherosclerosis and its serious consequences such as acute myocardial infarction (AMI), stroke, aortic aneurysms, and intimal hyperplasia. LT biosynthetic enzymes are expressed within atherosclerotic lesion, leading to production of cysteinyl-leukotrienes (Cys- LTs) and LTB4 that exert potent pro-inflammatory action through interaction with CysLT and BLT receptor subtypes expressed on inflammatory and structural cells within the vascular wall. Genetic variants in the genes of the 5-LO pathway have been associated with the risk of developing AMI and stroke. As a result, anti-LT have recently received renewed interest for the treatment of atherosclerosis and its ischemic complications. The aim of this short review is to summarize our current understanding of the role of LTs and their receptors in the genesis and progression of atherosclerosis and review the recent developments on the use of antagonists.
Keywords: Atherosclerosis, antileukotrienes, cardiovascular diseases, stroke, myocardial infarction
Current Drug Targets
Title: Leukotrienes and Atherosclerosis
Volume: 11 Issue: 7
Author(s): Graziano Riccioni, Magnus Back and Valerie Capra
Affiliation:
Keywords: Atherosclerosis, antileukotrienes, cardiovascular diseases, stroke, myocardial infarction
Abstract: Evidence from experimental and genetic studies suggest the existence of a potential link between the leukotrienes (LT) signalling cascade, and the pathogenesis/progression of atherosclerosis and its serious consequences such as acute myocardial infarction (AMI), stroke, aortic aneurysms, and intimal hyperplasia. LT biosynthetic enzymes are expressed within atherosclerotic lesion, leading to production of cysteinyl-leukotrienes (Cys- LTs) and LTB4 that exert potent pro-inflammatory action through interaction with CysLT and BLT receptor subtypes expressed on inflammatory and structural cells within the vascular wall. Genetic variants in the genes of the 5-LO pathway have been associated with the risk of developing AMI and stroke. As a result, anti-LT have recently received renewed interest for the treatment of atherosclerosis and its ischemic complications. The aim of this short review is to summarize our current understanding of the role of LTs and their receptors in the genesis and progression of atherosclerosis and review the recent developments on the use of antagonists.
Export Options
About this article
Cite this article as:
Riccioni Graziano, Back Magnus and Capra Valerie, Leukotrienes and Atherosclerosis, Current Drug Targets 2010; 11 (7) . https://dx.doi.org/10.2174/138945010791320881
DOI https://dx.doi.org/10.2174/138945010791320881 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Giant Cell Arteritis - Beyond the Headache
Current Rheumatology Reviews Contribution of Platelet-Derived CD40 Ligand to Inflammation, Thrombosis and Neoangiogenesis
Current Medicinal Chemistry Coarctation of the Aorta - An Evolution of Therapeutic Options
Current Cardiology Reviews Scaling Down SAGE: from miniSAGE to microSAGE
Current Pharmaceutical Biotechnology Why and how do Microbubbles Enhance the Effectiveness of Diagnostic and Therapeutic Interventions in Cerebrovascular Disease?
Current Pharmaceutical Design A Glimpse of Matrix Metalloproteinases in Diabetic Nephropathy
Current Medicinal Chemistry Is the Use of Autologous Platelet-Rich Plasma Gels in Gynecologic, Cardiac, and General, Reconstructive Surgery Beneficial?
Current Pharmaceutical Biotechnology Roles of miRNA in Cardiovascular Development and Dysfunction
Current Medicinal Chemistry Targeting α7 Nicotinic Acetylcholine Receptor to Combat Inflammation in Cardio-Cerebral-Vascular Diseases
Current Drug Targets Abnormal Peri-Organ or Intra-organ Fat (APIFat) Deposition: An Underestimated Predictor of Vascular Risk?
Current Vascular Pharmacology Therapeutic Interventions in the Glyc(oxid)ation Pathway
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Antagonists of Endothelin Receptors: Results and Perspectives
Current Pharmaceutical Analysis Disorders of Innate Immunity in Human ageing and effects of Nutraceutical Administration
Endocrine, Metabolic & Immune Disorders - Drug Targets Ventricular and Vascular Stiffening in Aging and Hypertension
Current Hypertension Reviews A Variant in the Endoglin Gene is Associated with the Development of Sporadic Intracranial Aneurysms
Current Neurovascular Research Sestrins: A New Kid for Stroke Treatment?
Current Drug Delivery Hyperpolarized <sup>13</sup>C MR Angiography
Current Pharmaceutical Design Endovascular vs. Open Repair of Abdominal Aortic Aneurysms and Renal Function
Current Vascular Pharmacology New Mechanisms and Targets of Subarachnoid Hemorrhage: A Focus on Mitochondria
Current Neuropharmacology CT-negative Subarachnoid Hemorrhage Caused by Telangiectasia: A Case Report
Current Medical Imaging